Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly (LLY) reported in-line fourth-quarter sales on Thursday, while reiterating a 2025 revenue guidance that implies the top line will grow at the same pace as it did last year. Revenue climbed ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

Stock futures are little changed as investors aim for a third-straight winning session. Google is the latest tech giant to ...

Eli Lilly and Co. (LLY) on Thursday reported fourth-quarter earnings of $4.41 billion. The Indianapolis-based company said it had profit of $4.88 per share. Earnings, adjusted for one-time gains and ...

At 09:52 a.m. ET, the Dow Jones Industrial Average rose 8.51 points, or 0.04%, to 44,892.21, the S&P 500 gained 13.84 points, ...

Futures tied to Wall Street's main indexes edged up on Thursday ahead of a wave of corporate earnings, while a seeming lull ...